Formycon
Germany - MartinsriedBiotechnology
Focus: Formycon is a German biotechnology company specializing in biosimilars with a focused pipeline in ophthalmology, particularly retinal diseases. The company has achieved commercial launches in the competitive anti-VEGF biosimilar space.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Formycon
AI assessmentNot HiringNo open roles listed right now. Follow Formycon to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Launch
Recently launched ranibizumab biosimilar competing in high-volume ophthalmology market with established clinical indication portfolio.
Help build intelligence for Formycon
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.